US OptionsDetailed Quotes
GRAL250117C15000
- 2.65
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open2.65Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover0.00%IV-32.04%PremiumJan 17, 2025Expiry Date10.97Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma9.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Grail Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
50
11
5
4
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina (ILMN.US)$ botched the acquisition of $Grail (GRAL.US)$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail (GRAL.US)$ why circuit breaker?
No comment yet
NoNo444 : TNXP TNXP!!
Prog : BUY APLD
PYUN970IHaveChosen : Jaguar8🫵
! As always, Thank you for this updated information. Time to dig in and do my DD!
Diaper Fund 4 MyGirl : Thank you
104994289 : TNXP!
View more comments...